Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
Merck buys ArQule and BTK drug for $2.7bnMerck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US Share XMerck buys ArQule and BTK drug for $2.7bnhttps://pharmaphorum.com/news/merck-buys-arqule-for/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
Sanofi snaps up Synthorx for $2.5bn, eyeing cancer immunotherapy combinationsSanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology Share XSanofi snaps up Synthorx for $2.5bn, eyeing cancer immunotherapy combinationshttps://pharmaphorum.com/news/sanofi-snaps-up-synthorx-for-2-5bn-eyeing-cancer-immunotherapy-combinations/
Nearly half of lymphoma patients alive after Gilead’s CAR-T therapyNearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, Share XNearly half of lymphoma patients alive after Gilead’s CAR-T therapyhttps://pharmaphorum.com/news/nearly-half-of-lymphoma-patients-alive-after-gileads-car-t-therapy/
Early data from Roche’s NHL drug mosunetuzumab steals the show at ASHThere’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising Share XEarly data from Roche’s NHL drug mosunetuzumab steals the show at ASHhttps://pharmaphorum.com/news/early-data-from-roches-mosunetuzumab-steals-the-show-at-ash/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
App helps cancer patients manage their medsA healthcare app due to launch at the end of this year aims to empower cancer patients and Share XApp helps cancer patients manage their medshttps://pharmaphorum.com/news/app-helps-cancer-patients-manage-their-meds/
FDA sets January action date for Keytruda in early bladder cancerMerck & Co/MSD has filed for approval of its PD-1 inhibitor Keytruda in a hard-to-treat form of bladder Share XFDA sets January action date for Keytruda in early bladder cancerhttps://pharmaphorum.com/news/fda-sets-january-action-date-for-keytruda-in-early-bladder-cancer/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
FDA grants AZ’s Imfinzi fast review in new lung cancer useThe FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung Share XFDA grants AZ’s Imfinzi fast review in new lung cancer usehttps://pharmaphorum.com/news/fda-grants-azs-imfinzi-fast-review-in-new-lung-cancer-use/
Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super Share XMerck & Co’s Keytruda shows promise with prostate cancer ‘super responders’https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/
NICE backs Ibrance for breast cancer via Cancer Drugs FundPfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced Share XNICE backs Ibrance for breast cancer via Cancer Drugs Fundhttps://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/
Blackstone and Ferring pump $570m into bladder cancer gene therapySwitzerland’s Ferring Pharmaceuticals has joined with US investor Blackstone Life Sciences to pump $570 million into a bladder Share XBlackstone and Ferring pump $570m into bladder cancer gene therapyhttps://pharmaphorum.com/news/blackstone-and-ferring-pump-570m-into-bladder-cancer-gene-therapy/
